chore: daily update 2026-08-18

themes/01-organoid-equipment.md

@@ -61,6 +61,7 @@ The state diagram shows the canonical CelVivo → 3Brain workflow: 3D suspension
 - **Bosnjakovic 2025 bioRxiv (PAH HepG2 3D spheroid, ClinoStar dynamic culture)** — 21-day maturation + 24h/96h BaP/BBF exposure; **4 metabolic markers (phenylalanine, TCA intermediates, GSH depletion, sphingolipid dysregulation) only appear in 3D, completely invisible in 2D**. Sales ammunition: "your 2D model is missing 100% of environmental toxicology early signals". Synthesis at [`/sources/literature-cel-bosnjakovic-2025-pah-deepread.md`](/sources/literature-cel-bosnjakovic-2025-pah-deepread.md).
 - **Miao 2025 Cell v2 (co-differentiation mesoderm + endoderm, vascularized lung/gut organoids, ClinoStar rotating culture)** — single 3D EB co-induction strategy yields **vHLPO with 7% ECs vs traditional HLPO 0%**, organ-specific endothelium + mesenchyme scRNA-seq validation, in-vivo functional integration with host circulation, FOXF1 mutation ACDMPV dual-pathology disease modeling. Product relevance: CelVivo ClinoStar rating 5 (co-differentiation depends on 3D EB self-organization in low-shear rotating culture — ClinoStar is the canonical hardware), HD-MEA rating 4, 3D bioprinting rating 3, patient-derived organoid drug screening rating 5. Synthesis at [`/sources/literature-miao-2025-cell-vascularization-v2-deepread.md`](/sources/literature-miao-2025-cell-vascularization-v2-deepread.md).
 - **Liu 2026 Nat Biomed Eng (shape-conformal porous framework for neural organoid e-phys, Rogers Lab)** — CelVivo ClinoStar rating 4 (organoid culture downstream of the shape-conformal framework; long-term maturation + functional readout is the canonical ClinoStar → HD-MEA workflow). Synthesis at [`/sources/literature-liu-2026-nbme-shape-conformal-organoid-deepread.md`](/sources/literature-liu-2026-nbme-shape-conformal-organoid-deepread.md). See 3Brain evidence for the HD-MEA read side.
+- **Quintard 2024 Nat Commun (microfluidic platform integrating functional vascularized organoids-on-chip, 2026-08-16)** — CelVivo ClinoStar rating 3 (upstream workflow: BVO differentiation day 0-15 needs rotating-wall suspension culture; ClinoStar is the canonical hardware for this stage; the paper's day 15 → chip-on-board handoff is the canonical CelVivo → organ-on-chip workflow). Mimetas OrganoPlate rating 4 (direct Phaseguide-based vascularized / kidney / intestine organ-on-chip competitor — Robin's portfolio does not currently cover Mimetas but the platform represents a candidate cross-sell if Robin's customers ask "where do I run my CelVivo-matured organoids in a vascularized microenvironment?"). Emulate Organ-Chip rating 3 (Colon-Intestine-Liver platform companion). 10 通道并行微流控芯片 + hiPSC-BVO + 间充质球体 + 胰岛球体 + 肺类器官 跨类器官验证; 血管层级化 37 µm 上游动脉-静脉 + 8 µm BVO 毛细管; 壁剪切 27-2000 s⁻¹ 完美匹配人体毛细血管生理范围 50-1900 s⁻¹. 4-commit LDR cycle 2026-08-16 (commits `0fc8db24` → `290e9635` → `24c713de` → `4073abf4` — last commit deleted the 3Brain reference per the SOP "硬门槛合规修正" cleanup rule because Quintard is organ-on-chip territory rather than 3Brain territory). Wiki IDs 1719/1720/1722, NocoDB Id 3297, DOI 10.1038/s41467-024-45710-4. Sales ammunition: "你的类器官前段培养到 day 15, 后段血管化怎么接? 我们的 CelVivo ClinoStar 提供 day 0-15 金标准旋转培养, 后接 Quintard 2024 微流控芯片做 30 天功能性血管化灌注". Customer entry: 药企临床前 (vascularized drug screening) + 微流控 organ-on-chip 平台集成商 (Mimetas / Emulate channel partners) + academic PI (vascular development / diabetes). Vault path: `obsidian-vault/Literature/Deep-Reads/Organoid/quintard_2024_vasorganoid_chip.md` (189 lines + 6 真图).
 - **Liang 2026 Sci Rep (mouse liver organoid 3-轨道 + fibrosis modeling, 2026-08-12)** — CelVivo ClinoStar rating 4 (P1-P10 长程扩增对应旋转培养 30+ 天无剪切; single DAPT only sustains P5, DAPT+Dex 协同才实现 P10 稳定成熟), CelVivo ClinoReactor rating 4 (单组织 3 轨道 [Hep/Cho/HSC] 分通道灌流; TGFβ 时间程序精确切换实现纤维化激活模型), CelVivo PhaseHolographic 成像 rating 3 (3D 球体直径/CV 实时 QC), 3Brain HD-MEA rating 3 (肝-神经互作延伸场景). 3 轨道 from 单份小鼠肝组织 (密度梯度离心 + 差速贴壁) → DAPT+Dex P1-P10 长程稳定成熟 (ALB / PAS / LDL / CYP 跨代保持) → TGFβ 5-7 天激活 qHSC → aHSC (Acta2/Col1a1 上调) → aHSC 共培养诱导 Hep-Orgs EMT (Snail/Twist/Vimentin ↑; ALB/CK8 ↓; Lgr5/EpCAM ↓; Ki67 ↓) = 体外肝纤维化模型. Wiki.js Id=1716, NocoDB Id=770, PMID 41857098. Page 946 9 项 SOP 重写版 + page 934 修齐 标杆 (4-commit LDR cycle 2026-08-12). **First deep-read whose `related:` field already names `[[MOC-类器官与3D培养]]`** on the day of publication — confirms MOC pattern in active use on real deep-reads. Vault path: `04-Literature/Deep-Reads/Liver/2026-08-12_Liang_2026_SciRep_liver_organoid_fibrosis_platform.md` (170 lines). Sales ammunition: "你的肝类器官只能短期培养? DAPT+Dex P1-P10 稳定成熟 + 单组织 3 轨道 + 14 天纤维化模型 — ClinoStar + ClinoReactor 一站搞定". Customer entry: 药企临床前 (抗纤维化药筛 14+ 天 3D 多细胞模型) + 临床肝活检中心 (1-2 mg 组织 → 3 周药敏 → ClinoReactor 6 通道一次测 6 药). Tracks in `/commitments.md` as `liang-2026-celvivo-clinostar-positioning`.
 - **Sales ammunition kit (CelVivo pricing + 8 Protocols + 5 app notes + 5 brand/whitepapers)** — Demo kit `10005-6` lists at €300 (Global Distributor Price, with special discount). 8 ClinoReactor Protocols cover prepare / media change / gardening / plate config / rotation-speed / alginate embed / VitroGel embed. 5 application notes cover HepG2/C3A liver, FTC-133 thyroid, NCI-H69V SCLC, TNBC, ClinoStar vs Orbital Shaker. Synthesis at [`/sources/sales-ammunition.md`](/sources/sales-ammunition.md).
 - **260528_CS vs OS app note (2026-07-17 deep read)** — ClinoStar vs Orbital Shaker shear-stress comparison for long-term 3D construct performance; ClinoStar has lower shear + long-term growth + better consistency. This is the **vs-competitor killer document** for "why not use an orbital shaker" customer questions.
@@ -93,6 +94,7 @@ The state diagram shows the canonical CelVivo → 3Brain workflow: 3D suspension
 
 - **China CDE cell & gene therapy classification rules (2026-07-24)** — affects CelVivo-class deals in the Chinese pharma R&D / CDMO customer base. Tracks in [`/commitments.md`](/commitments.md) `china-cde-cell-gene-therapy-rules-2026`.
 - **China Order No. 818 (effective 2026-05-01)** — accelerated clinical-translation pathway for cell therapy and 3D bioprinting at qualified hospitals. Tracks as `china-order-no-818-clinical-translation`.
+- **Guo 2026 Front Cell Dev Biol organoid IRB / ethics systematic review (2026-08-16)** — CelVivo ClinoStar ⭐⭐⭐⭐ clinical-translation IRB compliance; **Robin 推广 ClinoStar 给三甲医院时, 可附带 Guo 2026 框架作为增值**. The paper structures the IRB review framework as 7 mandatory points (sample provenance + donor informed consent + data privacy & de-identification + co-culture agency + animal welfare 3R + cross-border regulation + long-term storage & termination) + a 5-jurisdiction cross-border table (China《人类遗传资源管理条例》+《涉及人的生命科学和医学研究伦理审查办法》2023 vs US HIPAA + Common Rule + NIH GDS vs EU GDPR + Clinical Trials Regulation 536/2014 vs Japan / Korea). 3-commit LDR cycle 2026-08-16 (`2e6f5989` → `00f824f2` → `a4fa5a32`). Wiki.js ID 1724, NocoDB Id 3298, DOI 10.3389/fcell.2026.1721946. **Robin translated the paper into a customer-facing IRB application checklist template** at `templates/类器官IRB申请清单.md` v1.0 (180 lines; 7 mandatory points checklist + 5 customer Q&A + China vs International flow table + 10 attachments + 7 citations). Tracks in `/commitments.md` as `guo-2026-organoid-irb-checklist-rollout` (Owner: me; fold IRB application checklist into CelVivo industrial-customers program + Robin customer-training core material; commit the template and add a synthesis page at `/sources/literature-guo-2026-front-cell-dev-biol-organoid-ethics-deepread.md`). Vault path: `obsidian-vault/Literature/Deep-Reads/Organoid/guo_2026_organoid_ethical_review.md` (170 lines + 3 真图).
 - **China CGT 2026-07 developments** — Merck–Bio-Techne $11.3B acquisition, CARsgen satri-cel solid-tumor CAR-T approval (positive); gene-editing trial death + regulatory backlash (negative). Tracks as `china-cgt-2026-july-developments`.
 
 ## Cross-cutting relationship
@@ -112,8 +114,11 @@ The state diagram shows the canonical CelVivo → 3Brain workflow: 3D suspension
 | What is Liu 2026's shape-conformal neural organoid e-phys story? | [`/sources/literature-liu-2026-nbme-shape-conformal-organoid-deepread.md`](/sources/literature-liu-2026-nbme-shape-conformal-organoid-deepread.md) |
 | What is Sharma 2026's vascularized retinal organoid RGC story? | [`/sources/literature-sharma-2026-cell-stem-cell-vascularized-retinal-organoid-rgc-deepread.md`](/sources/literature-sharma-2026-cell-stem-cell-vascularized-retinal-organoid-rgc-deepread.md) |
 | What is Liang 2026's liver organoid fibrosis platform story? | `04-Literature/Deep-Reads/Liver/2026-08-12_Liang_2026_SciRep_liver_organoid_fibrosis_platform.md` (vault path; deep-read synthesis not yet split out to `/sources/`) |
+| What is Quintard 2024's vascularized organoid chip story? | `obsidian-vault/Literature/Deep-Reads/Organoid/quintard_2024_vasorganoid_chip.md` (vault path; deep-read synthesis not yet split out to `/sources/`) |
+| What is Guo 2026's organoid IRB / ethics story? | `obsidian-vault/Literature/Deep-Reads/Organoid/guo_2026_organoid_ethical_review.md` (vault path; deep-read synthesis not yet split out to `/sources/`) |
+| What is the IRB application checklist for organoid research? | `templates/类器官IRB申请清单.md` v1.0 (vault path; untracked) |
 | What distributors am I actually working with? | [`/sources/agents.md`](/sources/agents.md) |
 | Which Chinese dealers carry our brand? | [`/sources/distributors-china-2026.md`](/sources/distributors-china-2026.md) |
-| What regulatory shifts affect our Chinese pharma deals? | [`/commitments.md`](/commitments.md) China CDE / Order No. 818 / China CGT items |
+| What regulatory shifts affect our Chinese pharma deals? | [`/commitments.md`](/commitments.md) China CDE / Order No. 818 / Guo 2026 IRB / China CGT items |
 | What conferences is 3Brain at this season? | [`/commitments.md`](/commitments.md) `3brain-coreplate-2026-conference-positioning` |
 | What's the CelVivo → 3Brain joint workflow? | [`/themes/01-organoid-equipment.md`](/themes/01-organoid-equipment.md) (this page) Workflow chain section |